Results updated 18 Dec 2019
Regulations for country of origin labelling for complementary medicines have changed.
To see what has changed, visit the Competition and Consumer Amendments (Australian-made Complementary Medicines) Regulations 2019 on the Federal Register of Legislation.
Files:
- Decision Regulation Impact Statement, 1.2 MB (PDF document)
- Decision Regulation Impact Statement, 694.2 KB (Office Word 2007 XML document)
Published responses
View submitted responses where consent has been given to publish the response.
Overview
In February 2017 amendments were made to the Country of Origin Labelling (CoOL) laws that changed the basis for being eligible to make 'made in Australia' claims, and subsequently access the Australian Made, Australian grown (AMAG) logo.
The CoOL law amendments focused on the food industry and is mandatory for priority-foods. However, all other products and goods that wish to make an AMAG claim are also bound by the CoOL laws.
The complementary medicines sector has advised the government that many of their products are no longer eligible to use the AMAG logo, which will potentially effect the growth of the sector.
Regulation Impact Statement
This Consultation Regulation Impact Statement (RIS) discusses various options to assist the complementary medicines sector to regain access to the AMAG logo.
We will use the feedback obtained through this RIS to assist the government to make a decision that is in the best interest of all stakeholders.
What happens next
Comments on the Consultation Regulatory Impact Statement for origin claims in the Complementary Medicines Sector are now closed.
We are reviewing and analysing the submissions we received.
This feedback will inform consultation with the Commonwealth, state and territory governments, which will inform the Decision RIS.
Related
Regulation Impact Statement 1.2 MB (PDF document)
Regulation Impact Statement 739.2 KB (Office Word 2007 XML document)